Ro 25-6981 maleate
Cat. No. 1594
Chemical Name: (αR,βS)-α-(4-Hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidinepropanol maleate
Biological ActivityPotent and selective activity-dependent blocker of NMDA receptors containing the NR2B subunit. IC50 values are 0.009 and 52 μM for cloned receptor subunit combinations NR1C/NR2B and NR1C/NR2A respectively. Displays neuroprotectant effects in vivo and in vitro.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Fischer et al (1997) Ro 25-6981, a highly potent and selective blocker of N-Methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J.Pharmacol.Exp.Ther. 283 1285. PMID: 9400004.
Lynch et al (2001) Pharmacological characterization of interactions of RO 25-6981 with the NR2B (ε2) subunit. Eur.J.Pharmacol. 416 185. PMID: 11290368.
Kosowski and Liljequist (2004) The NR2B- selective N-methyl-D-aspartate receptor antagonist Ro 25-6981 [(±)-(R*,S*)-α-(4-hydroxyphenyl)-β-methyl-4-(phenylmethyl)-1-piperidine propanol] potentiates the effect of nicotine on locomotor activity and dopamine release in the nucleus accumbens. J.Pharmacol.Exp.Ther. 311 560. PMID: 15256539.
If you know of a relevant citation for this product please let us know.
Keywords: Ro 25-6981 maleate, supplier, Subtype-selective, NR2B, antagonists, Glutamate, NMDA, Receptors, N-Methyl-D-Aspartate, iGlur, Ionotropic, Ro25-6981, maleate
Find multiple products by catalog number
New Products in this Area
Non-competitive AMPA/kainate antagonistQNZ 46
NR2C/NR2D-selective NMDA receptor non-competitive antagonist
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.